Latest news
{{'2026-05-19T12:00:00Z' | dateFormatFilter}}
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
{{'2026-05-13T06:00:00Z' | dateFormatFilter}}
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
{{'2026-05-12T10:25:00Z' | dateFormatFilter}}
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
